Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) gets US Patent for its unique Kidney Cancer Test Print E-mail
By William Kent   
Thursday, 26 March 2015 15:27

Shares of Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) jumped 8% to $3.03 on moderate volume on Thursday after the company announced the new patent.

 

 Leading provider and developer of microRNA-based molecular diagnostics, Rosetta Genomics Ltd. (USA)(NASDAQ:ROSG), has confirmed receipt of Notice of Allowance for U.S. Patent Application No. 13/412,020, known as Gene Expression Signature for Classification of Kidney Tumors.

 

This patently is owned in combination Tel Hashomer Medical Research Ltd., the technology transfer firm of Chaim Sheba Medical Center in Israel.

The patent has a potential method which would identify four kinds of kidney cancer: oncocytoma, papillary (chromaphil) RCC, clear cell renal cell carcinoma (RCC) and chromophobe RCC in a human subject with renal cancer.

 

The consequence of imitation of diagnostic capability in renal oncocytoma was shown by recent health economics outcome review of management of kidney masses.

 

The study showed bad health and economic outcomes are results of poor pre-operative diagnosis and low rates of pre-nephrectomy biopsy.

 

The IMS LifeLink database analysis covered over 60 million commercially insured patients in the U.S and it has been found that almost 1 in 6 who had a nephrectomy for suspected renal cell cancer were later identified having benign disease. The impact in monitory terms is almost $26,500 per patient.

 

This is opposite to total expense of about $1,300 pre-operatively today and it has been projected that there are over 10,000 unnecessary surgeries annually in U.S. alone.

 

Kidney cancer ranks amongst the ten most common cancers in women and men both and accounts for over 3% adult malignancies causing over 14,000 deaths per year in the U.S. alone.

Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, stated that the 42 issue patents and 46 pending worldwide reflects the company’s intellectual property position in microRNA biomarker technology as well as in creating proprietary content in specialised medicine.

 

He added that long-term prognosis for the four subtypes makes the correct pathological diagnosis of a renal cancer critically important.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter